Tempus

Deep 6 AI Inc. operates an artificial intelligence-based platform that facilitates patient matching for clinical trials. The software analyzes both structured data, such as ICD-10 codes, and unstructured clinical data, including doctor’s notes and pathology reports, to extract critical clinical data points like symptoms, diagnoses, and treatments. By employing artificial intelligence and natural language processing, Deep 6 AI transforms fragmented medical documents into unified patient graphs that allow for more accurate matching of patients to complex clinical trial criteria. The platform not only identifies patients whose conditions may not be explicitly documented in medical records but also enhances the recruitment process by finding patients who more closely align with trial requirements. Founded in 2013 and based in Pasadena, California, Deep 6 AI was previously known as Deep 6 Analytics, LLC before rebranding in March 2017.

Ambry Genetics is a privately-held healthcare company that specializes in genetic testing solutions for inherited and non-inherited diseases. The company offers a comprehensive suite of services, including gene testing, classification, and sequencing. Ambry is committed to scientific collaboration, working alongside clinicians, patients, and researchers to advance medical knowledge. By sharing anonymized patient records with the global medical research community, Ambry aims to contribute to the understanding and management of human diseases, fulfilling the potential of the human genome. With its services accessible to a significant portion of U.S. patients covered by public and private insurers, Ambry Genetics plays a vital role in the evolving field of genetic diagnostics.

Personalis, Inc. is a cancer genomics company that specializes in sequencing and data analysis services to facilitate the development of personalized cancer therapies. The company offers the NeXT Platform, which delivers critical data for therapy development, therapy selection, and diagnostics. Additionally, Personalis provides a liquid biopsy assay that analyzes various human genes. Its services cater to a diverse clientele, including biopharmaceutical companies, academic institutions, non-profit organizations, diagnostics firms, and government agencies. The company focuses on advancing precision medicine and immunotherapy by providing detailed molecular insights into individual tumors and their interactions with the immune system. Founded in 2011 and headquartered in Menlo Park, California, Personalis has established partnerships to enhance its offerings and expand its impact in cancer treatment.

Dawson Forte Cashmere is a retailer of cashmere products, including gloves, scarves, and accessories. They offer cashmere clothing, portfolio of label knitwear made of silk and woollen materials, allowing for both men's and women's garments.

Mpirik is a healthcare intelligence platform that focuses on enhancing clinical decision-making by identifying critical findings and filtering out unnecessary data. The platform aggregates and standardizes health information, enabling effective communication between healthcare providers and patients. It tracks patient progress through disease stages, ensuring timely follow-ups and facilitating a more organized approach to patient care. By leveraging data analysis, Mpirik allows clinicians to screen patients for diseases with the accuracy and consistency of a computer algorithm, ultimately supporting improved health outcomes and operational efficiency in healthcare settings.

Arterys Inc. is a technology company that specializes in developing a cloud-based analytics platform designed to enhance medical imaging diagnostics. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a range of artificial intelligence solutions, including Cardio AI for cardiac image analysis, Lung AI for lung imaging, and Liver AI for liver assessments. Their platform provides radiologists with tools to visualize and quantify blood flow in the human body, facilitating improved patient care through advanced imaging techniques. The Arterys PHI Service allows physicians to access patient data remotely, enhancing the efficiency of medical practice. As a pioneer in internet-based medical imaging, Arterys combines web accessibility with FDA-cleared AI technology to deliver innovative clinical solutions aimed at transforming healthcare.

Arterys Inc. is a technology company that specializes in developing a cloud-based analytics platform designed to enhance medical imaging diagnostics. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a range of artificial intelligence solutions, including Cardio AI for cardiac image analysis, Lung AI for lung imaging, and Liver AI for liver assessments. Their platform provides radiologists with tools to visualize and quantify blood flow in the human body, facilitating improved patient care through advanced imaging techniques. The Arterys PHI Service allows physicians to access patient data remotely, enhancing the efficiency of medical practice. As a pioneer in internet-based medical imaging, Arterys combines web accessibility with FDA-cleared AI technology to deliver innovative clinical solutions aimed at transforming healthcare.

Highline Sciences is a full-service clinical contract research organization (CRO) that specializes in oncology. The company is dedicated to managing and executing both early and late-stage clinical trials, tailoring its approach to meet the unique requirements of each study. In addition to trial management, Highline Sciences offers services in clinical development consulting, clinical staffing, and marketing and commercial services, ensuring that clients receive comprehensive support throughout the clinical development process.

Akrivia Health specializes in delivering real-world data to enhance evidence generation and optimize clinical trials, particularly in the fields of mental health and dementia. The company offers an AI-driven software-as-a-service platform that focuses on managing patient records through a federated data governance model. In addition to supporting early-stage drug discovery, Akrivia Health aids in market analysis and clinical trial revenue management. Its robust AI-based clinical research database enables healthcare professionals to leverage clinical data literature, facilitating improved data management and the conduct of clinical research aimed at enhancing patient care.

AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in greater Atlanta, GA, the company’s initial focus has been oncology and personalized medicine. AKESOgen’s Research Services and Clinical/Regulatory Services include providing high-throughput biomarker profiling, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping and epigenomic analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. Their expertise in genomics and process control as well as their customer commitment make AKESOgen an ideal partner to execute and deliver on your projects.

8Trip, a China-based online travel service which connects suppliers with sellers. Currently, 8Trip covers the markets of Wuxi, Nanjing, and Anhui in China, and is planning to enter the Shanghai market next year. The company has partnerships with about 1,000 travel agencies and more than 4,000 service outlets. 8Trip was founded in December 2011 under the company name Octopus Online Tourism Development, with headquarters in Suzhou.

Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.